1450621-61-0

Basic information

• Product Name: 2-(4-((2S)-4-((6-amino-3-pyridinyl)sulfonyl)-2-((1Z)-1-propen-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol
• Synonyms: 2-(4-((2S)-4-((6-amino-3-pyridinyl)sulfonyl)-2-((1Z)-1-propen-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol
• CAS NO: 1450621-61-0
• Molecular Weight: 524.487
• Mol File: 1450621-61-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-(4-((2S)-4-((6-amino-3-pyridinyl)sulfonyl)-2-((1Z)-1-propen-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-((2S)-4-((6-amino-3-pyridinyl)sulfonyl)-2-((1Z)-1-propen-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol(1450621-61-0)
• EPA Substance Registry System: 2-(4-((2S)-4-((6-amino-3-pyridinyl)sulfonyl)-2-((1Z)-1-propen-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol(1450621-61-0)

Safety Data

• Hazardous Substances Data: 1450621-61-0(Hazardous Substances Data)

Upstream product

• 1361224-53-4 2-(4-((2S)-4-((6-amino-3-pyridinyl)sulphonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 1361224-52-3 2-(4-(4-((6-chloro-3-pyridinyl)sulphonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 1361224-48-7 2-(4-(4-((6-amino-3-pyridinyl)sulphonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 1361224-49-8 benzyl (2-((tert-butoxycarbonyl)amino)ethyl)(2-oxo-3-pentyn-1-yl)-carbamate 
• 1361224-50-1 benzyl 3-(propan-1-yn-1-yl)piperazine-1-carboxylate 
• 1361224-72-7 1,1,1,3,3,3-hexafluoro-2-(4-(2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-2-propanol 
• 1361224-51-2 benzyl 3-(1-propyn-1-yl)-4-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)-phenyl)-1-piperazinecarboxylate 
• 6684-39-5 2-chloropyridine-5-sulfonyl chloride 

Relevant articles and documents

SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN

The present invention relates to sulfonyl compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.